Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years. For more information, please visit https:/…

Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious t…

Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI. Topics include: challenges in developing bioassays for cell & gene …

Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health.For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics…

Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA. Topics include cell-free diagnostics in precision medicine, transformation & growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead.For more inform…

Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research.For more information, please visit https://www.MolecularDXEurope.com/Point-of-Care-DxCambridge Healthtech Podcasts

Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential.For more information, please visit https://www.TriConference.com/Digital-PathologyCambridge Healthtech Podcasts

Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently.For more information…

Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process.For more information, please visit https://www.triconference.com/Companion-DiagnosticsCambridge Healthtech Podcasts

Dr. Jennifer Chadwick shares her journey from academia to industry, and the best advice that got her to where she is today.Cambridge Healthtech Podcasts

For decades, high-performance computing (HPC) has played a crucial role in advancing healthcare. Enabled by techniques like next-generation sequencing (NGS), modern computer systems have helped us understand the biology of disease and helped facilitate the development of newer more effective drugs. While once deployed mainly in research, today HPC …

Dr. Bradley Perkins develops a digital platform that can estimate personalized ten year mortality risk. In this podcast, he shares with us what this platform is and how it works to protect and improve the health of individuals and families. In the era of personalized medicine, Dr. Perkins explains what the necessary steps to bring this platform to …

A re-upload of a podcast with Sandy Aronson, Executive Director, IT, Partners HealthCare Center for Personalized Genetic MedicineCambridge Healthtech Podcasts

A re-upload of a podcast with Brian Dixon, MPA, Ph.D., FHIMSS, Assistant Professor, Health Informatics, Indiana University; Research Scientist, Regenstrief Institute; Investigator in Residence, Department of Veterans AffairsCambridge Healthtech Podcasts

A re-upload of a podcast with Marc Berger, M.D., Vice President, Real World Data & Analytics, PfizerCambridge Healthtech Podcasts

Prof. Dai Fukumura gives a preview of his talk, shares some challenges of reprograming tumor microenvironment and what he would like to see more in this field.For more information, please visit http://www.DiscoveryOnTarget.com/Tumor-Myeloid-Cells/Cambridge Healthtech Podcasts

Dr. Jeffrey Miller shares his experience in NK cell field in the last 20 years, comparing NK cells with T cells and their cost differences along with giving some advice to the young scientists in the field.For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/…

Dr. James Trager shares a preview of his talk at the NK cell-based cancer immunotherapy meeting in Boston, discusses his next step in research and the vision of Nkarta in NK cell therapy development and what he’s looking forward to at this meeting such as the topics of inhibition of MIC protein shedding and NK cell metabolism.For more information, …

Dr. Florian M. Wurm, Swiss Federal Institute of Technology Lausanne (EPFL) and ExcellGene SA speaks to Cambridge Healthtech Institute on 9 July 2018. He will be the keynote presenter during the Optimising Expression Platforms conference at PEGS Europe, 12-16 November 2018 in Lisbon, Portugal. For more information, please visit http://www.PEGSummitE…

Dr. John Haurum shares his perspective on the future of bispecific antibodies in the next 5 years, common myths about immune system activation using bispecifics and some novel compounds inside and outside of IO fields that he’s looking forward to the most at the Bispecific Antibody Pipeline Congress.For more information, please visit http://www.Bis…

Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern CaliforniaDr. Jennifer Dien Bard shares her insights into what the biggest challenges and opportunities are in implementing molecular point-of-care testing for infectious disease diagnostics, and rapid genetic and phenotypic susceptibility testing. Jennifer will be s…

Prof. Massimo Cristofanilli shares his perspective on the future of liquid biopsy, the complementary purposes of CTC and cfDNA technologies, and when one should expect clinical utility of liquid biopsies.For more information, please visit http://www.NextGenerationDx.com/Circulating-Tumor-Cells/Cambridge Healthtech Podcasts

Dr. Bruce Quinn talks about his latest work, challenges to implementing precision medicine, advice for overcoming them and tips for integrating into the clinic. He discusses exciting new developments that are emerging and where the field is heading.For more information, please visit http://www.NextGenerationDx.com/Commercialization-Molecular-Diagno…

Daryl Pritchard of PMC speaks to CHI on May 4th, 2018. Darryl will be speaking at a shared session between the Coverage and Reimbursement for Advanced Diagnostics Track and the Precision Medicine tracks at the upcoming Next-Generation Diagnostic Summit that is held from August 20th to the 24th in Washington, D.C Topics include the chicken-or-the-eg…

Paul Yager of University of Washington speaks to CHI on May 4, 2018. Dr. Paul Yager from the University of Washington. Dr. Yager will be speaking at the Enabling Point-of-Care Diagnostics and the Microfluidics and Lab-on-a-Chip Devices for point-of-care testing tracks at the upcoming Next Generation Diagnostic Summit that is held from August 20th t…

Suman Bose of Massachusetts Institute of Technology speaks to CHI on May 3, 2018. Dr. Bose will be speaking at the Single Cell Analysis and at the Microfluidics and Lab-on-a-Chip Devises for point of care testing tracks at the upcoming Next Generation Diagnostics Summit that is held from August 20th through the 24th in Washington, D.C. Topics inclu…

Dr. James Hendler of Rensselaer Polytechnic Institute speaks to Cambridge Healthtech Institute on April 13, 2018. He will be a presenter during the Machine Learning and Data Visualization & Exploration Tools tracks at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include:1) What led you to work on precis…

Dr. Catherine Brownstein of Boston Children’s Hospital and Harvard Medical School speaks to Cambridge Healthtech Institute on April 10, 2018. She will be a presenter during the Clinical Genomics track at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include:1) Let’s touch upon your gene discovery work. W…

Dr. Nirmala Shenoy of Rochester Institute of Technology speaks to Cambridge Healthtech Institute on April 6, 2018. She will be a presenter during the Data Transfer track at Bio-IT World Conference & Expo, May 15-17, 2018 in Boston, Massachusetts. Topics Questions Include:1) Why have you focused your recent research on Internet architectures and pro…

Tim Sweeney spoke to CHI to discuss his company’s work in using host response to diagnose and risk stratify patients with sepsis infections. He also discusses current shortcomings sepsis diagnostics, as well as what he sees as barriers in implementing rapid diagnostics and how the field is moving forward to overcome these barriers.For more informat…

Dr. Choi-Fong Cho of Harvard Medical School spoke to CHI to discuss her breakthrough research and the development of BBB organoids to be used as a next-generation screening model for brain-penetrating molecules. She discusses next steps in her research, including investigating new compounds and drugs with this platform, as well as the potential to …

Dr. Andrew Bradbury talks about his latest work using NGS to build a single donor library, and shares lessons he has learned along the way. He describes the unique approach they are using at Specifica and outlines tips for creating antibody libraries with improved diversity and developability.For more information, please visit http://www.PEGSummit.…

Dr. Andreas Stange of TÜV SÜD talks about the practical impact of the new IVD regulation, how it will affect manufacturers and notified bodies, challenges in validation, and practical advice to prepare for these changes in companion diagnostics.For more information, please visit http://www.MolecularDXEurope.com/MDXE_Content.aspx?id=190671…

Dr. Evi Lianidou outlines what she considers some of the greatest obstacles in CTC analysis. She also shares her vision for clinical utilities of epigenetics in CTC and comments on some of the most exciting new studies and emerging technologies in CTC field, along with some advice for the CTC community in order to move liquid biopsy field forward.F…

Dr. Jorg Tost recently spoke to CHI to discuss his work with the ice-COLD-PCR assay and how it is addressing current challenges in cfDNA analysis. He also discusses challenges related to data, new technologies, and including other biomarkers in addition to cfDNA for the most complete and accurate analysis. Dr. Tost is speaking at the Enabling Techn…

As more patients become connected, there’s a new data source that can help us understand and engage patients-- data collected passively through wearables, devices, apps and sensors. Envision being able to gather minute-level data directly from patients, monitor adherence to a protocol outside of brick and mortar walls, and enroll patients into a st…

Cambridge Healthtech Institute’s Kent Simmons recently spoke with Dr. David Johnson, CEO of GigaGen, about his upcoming presentation “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods”, to be delivered in the Engineering Antibodies meeting at the 2018 PEGS Boston. PEGS is scheduled for…

Patrizia Paterlini-Brechot spoke to CHI to discuss her work in cell-based non-invasive prenatal diagnosis and some of the challenges in commercializing this technique. She also discusses the impact commercialized NIPD tests will have on the field of prenatal diagnosis and some of the new frontiers she expects will be next. Dr. Paterlini-Brechot is …

Dr. David Barton summarizes the new EU IVD regulations and highlights their key features. He will explain what the ramifications of introducing these new regulations for labs and manufacturers will be and advice for people preparing for the change.For more information, please visit http://www.MolecularDXEurope.com/mdxe_content.aspx?id=190671…

Steven Walfish of the USP recently spoke with CHI about his role in updating the USP Bioassay Chapters. He is currently leading the General Chapters Statistical Expert Committee. Steven also remarks on current challenges and how new technologies are changing the field of bioassays. To hear more, don’t miss his presentation in Optimizing Bioassays f…

Dr. William Hallett outlines what he considers some of the greatest obstacles to assess immunogenicity of biologics. He also comments on the reason behind the new requirement for lower cut-point in assays, how to accelerate Biobetters to the market in the world of Biosimilars, and advice for the industry in biologic development to accelerate FDA ap…

An interview with the 2018 Young Scientist Keynote, Dr. Kipp Weiskopf. Insights into new exciting developments in the growing field of cancer immunotherapy, perspectives on where this field is heading, and trends shaping the next generation of cancer immunotherapy.For more details, please visit: http://www.PEGSummit.com/Plenary-Keynote/…

Débora Araujo of Boehringer Ingelheim spoke to CHI to discuss her expertise in clinical trial agreements and some of the daily challenges she faces in negotiations and contracts. She specifically discusses some of the key barriers within and beyond the legal language of CTAs and also shares highlights from her forthcoming book, The Four Villains of…

Dr. Wells, Professor of Pharmaceutical Chemistry at the University of California, San Francisco, shares insights about his upcoming and the keynote presentation in the Emerging Technologies for Antibody Discovery conference being held on January 11th and 12th at PepTalk.For more information, please visit http://www.CHI-PepTalk.com/Antibody-Discover…

In this podcast from CHI on September 20, 2017, Stephen Carey speaks about Omniox’s quest to deliver oxygen into the tumor microenvironment to improve immunotherapy response. He also remarks on the challenges facing tumor microenvironment research and strategies to overcome them. To see him in person, check out the Targeting the Tumor Microenvironm…

Real World Evidence (RWE) is today’s big data challenge in Life Sciences. Medical records, registries, consultation reports, insurance claims, pharmacy data, social media, and patient surveys all contain valuable insights that Life Sciences organizations need to ascertain and prove the safety, efficacy and value of their drugs and medical devices. …

In this podcast from CHI on September, Vancheswaran Gopalakrishnan and Jennifer Wargo speak about their work at the MD Anderson Cancer Center to understand the role of the microbiome in melanoma therapies, and the challenges that microbiome researchers are facing as this emerging field continues to move forward. To see him in person, check out the …

Dr. Neeta Vora of University of North Carolina Chapel Hill spoke to CHI to discuss new opportunities and challenges in fetal whole exome sequencing for prenatal diagnosis. She discusses technical challenges, issues surrounding patient counseling, the potential for performing exome sequencing on noninvasively obtained samples, and her current resear…

This podcast highlights the Plenary Keynote presentation that John Lambert will be giving at PEGS Europe, 13 November 2018 in Lisbon, Portugal. Dr. Lambert discusses the difficulties of bringing novel constructs to market; advice for people introducing new ADC products in the clinical setting; and some of the most exciting new developments and emer…

Tauseef Butt, CEO of Progenra Inc. speaks to CHI on September 8, 2017. Dr. Butt will be presenting during Immunomodulatory Small Molecules and Targeting the Ubiquitin Proteasome System, taking place this September 27-28 at Discovery on Target in Boston, MA.Topics include the benefits and challenges of immunomodulatory small molecules, Ubiquitin Pro…